Sanofi picked up Blueprint Medicines in a deal worth up to $9.5 billion. Bristol Myers Squibb will pay $1.5 billion upfront ...

Biontech SE and Bristol Myers Squibb Co. are teaming up to develop Biontech’s bispecific antibody targeting PD-L1 and VEGF-A, BNT-327, in a deal possibly worth over $11 billion. The companies will ...

In the 599-patient study, those on Wegovy alone lost about 7.9 pounds of muscle, while those on a combination of Regeneron's trevogrumab and Wegovy lost up to 4.2 pounds. Sanofi to buy US biopharma ...

Regeneron said on Monday its experimental drug helped patients preserve up to 51% of lean mass and lose more fat when used in ...

Itepekimab met the primary endpoint in one of two COPD phase 3 studies AERIFY-1 study met its primary endpoint of a statistically significant reduction in moderate or severe exacerbations in former ...

In light of the significant drop in Regeneron’s stock price, a natural question emerges: is REGN now a viable buying ...

Under terms of the deal, Bristol Myers will pay $1.5 billion upfront, and a total of $2 billion in anniversary payments for the next few years to co-develop and co-sell BioNTech's BNT327 for the ...

Sanofi and Regeneron have reported that the Phase III AERIFY-1 trial of the fully human monoclonal antibody itepekimab.

All three major averages closed out May with sizable gains Friday, with the S&P 500 and Nasdaq Composite seeing their best ...

Paris: Sanofi has announced that the AERIFY-1 phase 3 study evaluating itepekimab in former smokers with inadequately ...

Sanofi & Regeneron announce itepekimab meet the primary endpoint in one of two COPD phase 3 studies: Paris Saturday, May 31, 2025, 10:00 Hrs [IST] The AERIFY-1 phase 3 study evalu ...

Intellia’s stock fell 23% after one patient in its Phase III MAGNITUDE trial developed severe liver toxicity that later ...